|Targets||Raf | VEGFR|
|Description||This active molecular is a Proto oncogene protein b raf and Vascular endothelial growth factor A inhibitor originated by ArQule. ARQ 736 is effective in killing cancer cell lines that harboring at least one mutated b raf allele. The b raf protein is really a very important signaling molecule in the MAPK (mitogen activated protein kinase) signaling pathway and it relates to pathogenesis of variety kinds of cancer. In Mar 2014, Phase-I for Solid tumours (late-stage disease) was discontinued in USA.|
|Synonyms||ARQ 736 disodium salt; ARQ736 disodium salt; ARQ-736 disodium salt; sodium (R)-(3-(5-(2-((1-((1-methyl-1H-pyrazol-3-yl)sulfonyl)piperidin-3-yl)amino)pyrimidin-4-yl)imidazo[2,1-b]oxazol-6-yl)phenoxy)methyl phosphate;1228237-47-5 free acid|
|Solubility||Soluble in DMSO, not in water|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
Cabozantinib malate (XL184)
Cabozantinib malate is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL w...
MLN2480 is an oral, selective pan-Raf kinase inhibitor. The Raf kinases (A-Raf, B-Raf and C-Raf) are key regulators of cell proliferation and survival within th...
Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.
MCP110 is an Ras/Raf-1 interaction inhibitor. The Ras signaling pathway is activated either by direct mutation of Ras or its effector B-Raf. MCP110 was shown to...
PLX8394 is an orally bioavailable inhibitor of serine/threonine-protein kinase B-raf (BRAF) protein with potential antineoplastic activity. PLX8394 appears to s...
ZK-261991 is an orally active VEGFR tyrosine kinase inhibitor with an IC50 of 5 nM for VEGFR2. The high efficacy, including tumour regression in established tum...
Motesanib Diphosphate is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more...
This active molecular is a novel , paradox-breaking pan-RAF inhibitor with anti-SRC activity and it blocked growth of BRAF-mutant and NRAS-mutant melanoma cells...